CTM Biomedical introduced two new larger CTM Paste Human Placental Connective Tissue Allografts: CTM Paste XL and XXL, containing 450 mg and 750 mg of human placental connective tissue particulate, respectively. The new products will be available for use by surgeons by the end of April 2023.
CTM also made a charitable donation to Allegheny Health Network to create the AHN Connective Tissue Matrix Research Fund. The fund will exclusively support Human Placental Connective Tissue Matrix Allograft Research, both preclinical and clinical research that contributes to the scientific knowledge and understanding of the biological and physiological mechanisms of tissue repair in the presence of human particulate placental connective tissue matrix allografts.
“Surgeons know that many post-operative complications are biologic issues, resulting from poor tissue repair. Pairing surgical repair with a connective tissue allograft, with the ideal extracellular matrix contained in CTM Paste, supports the body in remodeling constructively,” said Kelly Hiatt, M.D., PhD, Chief Scientific Officer of CTM. “These larger volume allografts allow surgeons to introduce functional native extracellular matrix components, including collagen scaffold and growth factors, into larger areas of damaged tissue along with concentrated growth factors that leverage tissue specific progenitors to complete the repair.”
CTM Biomedical introduced two new larger CTM Paste Human Placental Connective Tissue Allografts: CTM Paste XL and XXL, containing 450 mg and 750 mg of human placental connective tissue particulate, respectively. The new products will be available for use by surgeons by the end of April 2023.
CTM also made a charitable donation to Allegheny...
CTM Biomedical introduced two new larger CTM Paste Human Placental Connective Tissue Allografts: CTM Paste XL and XXL, containing 450 mg and 750 mg of human placental connective tissue particulate, respectively. The new products will be available for use by surgeons by the end of April 2023.
CTM also made a charitable donation to Allegheny Health Network to create the AHN Connective Tissue Matrix Research Fund. The fund will exclusively support Human Placental Connective Tissue Matrix Allograft Research, both preclinical and clinical research that contributes to the scientific knowledge and understanding of the biological and physiological mechanisms of tissue repair in the presence of human particulate placental connective tissue matrix allografts.
“Surgeons know that many post-operative complications are biologic issues, resulting from poor tissue repair. Pairing surgical repair with a connective tissue allograft, with the ideal extracellular matrix contained in CTM Paste, supports the body in remodeling constructively,” said Kelly Hiatt, M.D., PhD, Chief Scientific Officer of CTM. “These larger volume allografts allow surgeons to introduce functional native extracellular matrix components, including collagen scaffold and growth factors, into larger areas of damaged tissue along with concentrated growth factors that leverage tissue specific progenitors to complete the repair.”
Copy to clipboard 
